PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Case Study

Volume 6 Issue 3

SGLT2 Inhibitor-Induced Onychomycosis in a Patient with IgA Nephropathy: A Case Report

Arjun Dang, Mankul Goyal, Ashima Jain Vidyarthi and Binish Jawed*

February 26, 2025

DOI : 10.56831/PSMPH-06-199

View PDF

Abstract

We report the case of a patient with a 2-year history of IgA nephropathy who was prescribed an SGLT-2 inhibitor. Within a month of initiating therapy, the patient developed onychomycosis, which was confirmed by fungal culture. Treatment with antifungal agents resulted in significant improvement. This case underscores the potential for fungal infections to occur in areas beyond the genito-urinary region in patients taking SGLT-2 inhibitors. Although the link between SGLT-2 inhibitors and onychomycosis is not well documented, our findings suggest a need for further investigation into this association and the risk factors involved.

Keywords: nail diseases; anti-fungal treatment; fungal infection; medication-induced nephropathy; sglt-2 inhibitor; onychomycosis

References

  1. Kim GW and Chung SH. “Clinical implication of SGLT2 inhibitors in  type 2 diabetes”. Arch Pharm Res 37.8 (2014): 957-966.
  2. Lv X., et al. “Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization study”. Front Pharmacol 15 (2024): 1399881.
  3. Barratt J and Floege J. “SGLT-2 inhibition in IgA nephropathy: the new standard of care?”. Kidney Int 100.1 (2021): 24-26.
  4. Scheen AJ. “An update on the safety of SGLT2 inhibitors”. Expert Opin Drug Saf 18.4 (2019): 295-311.
  5. Bartolo C., et al. “Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports”. BMC Infect Dis 21.1 (2021): 284.
  6. Unnikrishnan AG., et al. “Genital infections with sodium glucose cotransporter-2 inhibitors: Occurrence and management in patients with Type 2 diabetes mellitus”. Indian J Endocr Metab 22 (2018): 837-42.
  7. Wicik Z., et al. “Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis”. Front Pharmacol 13 (2022): 901340.
  8. Beitelshees AL, Leslie BR and Taylor SI. “Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research”. Diabetes 68.6 (2019): 1109-1120.